Melmark Services
Melmark, Inc.

Howard Mayer, MD, was most recently Executive Vice President, Head of Research and Development at Ipsen Pharmaceuticals from 2019-2023. He has served as an independent director on both public and private boards, including PepGen Inc, Kaerus Bioscience and Walden Biosciences today. He currently provides strategic and clinical/regulatory guidance to biopharmaceutical companies, and sits on several scientific advisory boards. Howard previously served as a board member of the New England Chapter of Autism Speaks.

Previously, Howard was Senior Vice President, Chief Medical Officer at Shire. Dr. Mayer joined Shire in 2012 and was responsible for global clinical development across the rare genetic diseases, hematology, immunology, oncology, GI/metabolic, neuroscience and ophthalmology therapeutic areas. Previously he served as chief medical officer at EMD Serono, a division of Merck KGaA, since 2009. Prior to that, he held a variety of global roles at Pfizer Inc. over nearly eight years, including head of clinical development and medical affairs for Virology/Infectious Diseases. Howard was a founding member of the Autism Research Unit at Pfizer. Prior to joining Pfizer, he served as director of Infectious Diseases Clinical Research at Bristol-Myers Squibb for five years.

Dr. Mayer obtained his BA from the University of Pennsylvania and his M.D. from Albert Einstein College of Medicine in New York, which was followed by an internship and residency at Mount Sinai Hospital and an Infectious Diseases fellowship at Harvard Medical School. In 2011 and in 2017, he was honored by PharmaVoice as one of the 100 Most Inspiring People in the Life Sciences Industry.

Howard resides in Lexington, MA with his wife Mara. They have two children, Jordan and Aubrey.